Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers
Addiction · 2023
DOI: 10.1111/add.16144 ↗At a glance
Journal article in Addiction, 2023. Written by Simon Jangard and 8 co-authors. Institution: Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden. Major MEDLINE topics: Alcohol Drinking, Alcoholism, Corpus Striatum, Receptors, Dopamine D2. Cited 8 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Vetenskapsrådet, Forskningsrådet om Hälsa, Arbetsliv och Välfärd.
Abstract (original language)
Background and aims Whereas striatal dopamine D2 receptor (D2R) availability has shown to be altered in individuals with alcohol use disorder (AUD) and in healthy individuals with a family history of AUD, the role of D2R in the development of AUD is unknown. In this positron emission tomography (PET) study, we measured whether D2R availability is associated with subsequent alcohol use and alcohol‐related factors, at a follow‐up 8 to 16 years post‐PET scan, in social drinkers.
Design
Longitudinal study investigating the association between PET data and later self‐report measures in healthy individuals.
Setting
Academic research imaging centre in Stockholm, Sweden.
Participants
There were 71 individuals (68 of whom had evaluable PET data, 5 females, 42.0 years mean age) from a series of previous PET studies.
Measurements
One PET examination with the D2R antagonist radioligand [ 11 C]raclopride at baseline and self‐report measures assessing alcohol use, drug use, impulsivity, reward sensitivity and family history of alcohol or substance use disorder at follow‐up.
Findings
We found no evidence for an association between D2R availability and later alcohol use (B = −0.019, B 95% CI = −0.043 to −0.006, P = 0.147) nor for the majority of the alcohol‐related factors (B 95% CI = −0.034 to 0.004, P = 0.273–0.288). A negative association with a small effect size was found between D2R availability and later impulsivity (B = −0.017, B 95% CI = −0.034 to −0.001, P = 0.046).
Conclusions
Low striatal dopamine D2 receptor availability may not be a strong predictor in the development of alcohol use disorder.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden.
- Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Psychiatry, Columbia University, New York City, New York, USA.
- Department of Biostatistics, Columbia University Mailman School of Public Health, New York City, New York, USA.
- Neurobiology Research Unit, Copenhagen University Hospital, Copenhagen, Denmark.
- Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden.
ORCID profiles: Simon Jangard
Funding
- Vetenskapsrådet
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Cite
APA
Jangard, S., Jayaram-Lindström, N., Isacsson, N. H., Matheson, G. J., Plavén-Sigray, P., Franck, J., Borg, J., Farde, L., & Cervenka, S. (2023). Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. Addiction. https://doi.org/10.1111/add.16144
Vancouver
Jangard S, Jayaram-Lindström N, Isacsson NH, Matheson GJ, Plavén-Sigray P, Franck J, et al. Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers. Addiction. 2023. doi:10.1111/add.16144
BibTeX
@article{Jangard2023,
author = {Jangard, Simon and Jayaram-Lindström, Nitya and Isacsson, Nils Hentati and Matheson, Granville James and Plavén-Sigray, Pontus and Franck, Johan and Borg, Jacqueline and Farde, Lars and Cervenka, Simon},
title = {Striatal dopamine D2 receptor availability as a predictor of subsequent alcohol use in social drinkers},
journal = {Addiction},
year = {2023},
doi = {10.1111/add.16144}
}
EUVIMED